Lexeo Therapeutics, Inc./$LXEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Ticker
$LXEO
Sector
Primary listing
Employees
59
Headquarters
Website
LXEO Metrics
BasicAdvanced
$387m
-
-$1.33
1.53
-
Price and volume
Market cap
$387m
Beta
1.53
52-week high
$10.99
52-week low
$3.60
Average daily volume
840k
Financial strength
Current ratio
14.156
Quick ratio
13.605
Long term debt to equity
2.017
Total debt to equity
3.181
Interest coverage (TTM)
-1,164.11%
Profitability
EBITDA (TTM)
-97.184
Management effectiveness
Return on assets (TTM)
-32.50%
Return on equity (TTM)
-54.75%
Valuation
Price to book
1.58
Price to tangible book (TTM)
1.58
Price to free cash flow (TTM)
-3.289
Free cash flow yield (TTM)
-30.40%
Free cash flow per share (TTM)
-1.499
Growth
Earnings per share change (TTM)
-59.68%
3-year earnings per share growth (CAGR)
-67.65%
LXEO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs